TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1535788

Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate for 21 days combined with 250 micrograms levonorgestrel for the last ten days
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate for 21 days combined with 10 mg medroxyprogesterone acetate for the last ten days
Number of subjects: 29
Study: 6318543

Group type: EXPERIMENTAL
Intervention: MK-521 20 mg once daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of MK-521 and Hydrochlorothiazide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31264767

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 75 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 30646261

Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) plus practice facilitation (PF)
Number of subjects: 6699

Group type: COMPARATOR
Intervention: Clinical decision support (CDS)
Number of subjects: 6699
Study: 25926620

Group type: EXPERIMENTAL
Intervention: Telcagepant 140 mg
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1334
Study: 25282309

Group type: EXPERIMENTAL
Intervention: Opioid attentional bias (AB)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Opioid attentional bias for 200 ms cues
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cue-elicited craving
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Regression analyses controlling for pre-treatment opioid dependence diagnosis, opioid misuse, and pain severity
Number of subjects: 47
Study: 22582760

Group type: EXPERIMENTAL
Intervention: Stationary cycling intervention for 3 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 20433326

Group type: EXPERIMENTAL
Intervention: High Negative/Poorer Attention group
Number of subjects: 77
Study: 18585976

Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic biliary drainage (PTBD)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Endoscopic stenting (ES)
Number of subjects: 54
Study: 15922197

Group type: EXPERIMENTAL
Intervention: Preoperative MRCP (group 2)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC) and intraoperative cholangiography (IOC) (group 1)
Number of subjects: 63
Study: 12234505

Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine (20 cc of 2% intrarectal lidocaine 20 minutes before biopsy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (same amount of serum physiologic)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 10521108

Group type: EXPERIMENTAL
Intervention: Purified FSH (75 IU FSH, <1 IU LH) for > or = 50 days before oocyte retrieval
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 78
Study: 8720265

Group type: EXPERIMENTAL
Intervention: Arthroscopic synovectomy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Open synovectomy
Number of subjects: 58
Study: 1775606

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion testing (TFD)
Number of subjects: 115
Study: 7006882

Group type: COMPARATOR
Intervention: Sublingual nitroglycerin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Erythrityl tetranitrate (ETN) - all forms
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral ETN
Number of subjects: 15
Study: 31481605

Group type: EXPERIMENTAL
Intervention: AsthmaTuner
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: AsthmaTuner (used once a week or more)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 77
Study: 28001305

Group type: EXPERIMENTAL
Intervention: Patient decision aid video with culturally tailored information about colorectal cancer screening
Number of subjects: 89

Group type: COMPARATOR
Intervention: Attention control video about hypertension
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study: 26489054

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 22926481

Group type: EXPERIMENTAL
Intervention: Malic acid 1%
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 21116652

Group type: EXPERIMENTAL
Intervention: Eszopiclone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 19412512

Group type: EXPERIMENTAL
Intervention: Scoring system for malignancy prediction based on TRUS findings
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: TRUS findings (shape, margin irregularity, vascularity)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis
Number of subjects: 350
Study: 17070593

Group type: EXPERIMENTAL
Intervention: Femtosecond laser for LASIK
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mechanical microkeratome LASIK
Number of subjects: 100
Study: 15001203

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 72
Study: 12370218

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Bx VELOCITY stent (SES)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Bare metal Bx VELOCITY stent (BS)
Number of subjects: 238
Study: 9847643

Group type: EXPERIMENTAL
Intervention: High-dose propofol (0.3 mg/kg plus 10 mg/kg/h perfusion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol with nitroprusside (8 mg/kg/h perfusion)
Number of subjects: 40
Study: 9734496

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 3000 mg/day
Number of subjects: 650
Study: 1884720

Group type: EXPERIMENTAL
Intervention: Diltiazem 120-360 mg/day
Number of subjects: 128

Group type: COMPARATOR
Intervention: Metoprolol 50-200 mg/day
Number of subjects: 128
Study: 6347922

Group type: EXPERIMENTAL
Intervention: Topical clindamycin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30711602

Group type: EXPERIMENTAL
Intervention: Time pressure
Number of subjects: 40

Group type: COMPARATOR
Intervention: No time pressure
Number of subjects: 40
Study: 26908586

Group type: EXPERIMENTAL
Intervention: High perceived control and high preference for control
Number of subjects: 119

Group type: COMPARATOR
Intervention: Low perceived control or low preference for control
Number of subjects: 119
Study: 27040154

Group type: EXPERIMENTAL
Intervention: Carnosine 2 g daily for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24294984

Group type: EXPERIMENTAL
Intervention: Adherence promotion program
Number of subjects: 86
Study: 23182488

Group type: EXPERIMENTAL
Intervention: 3-week course
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 6-week course
Number of subjects: 37

Group type: COMPARATOR
Intervention: Baseline scores
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison of course lengths
Number of subjects: 37
Study: 20740485

Group type: EXPERIMENTAL
Intervention: Real-rTMS (90% of resting motor threshold, 5 Hz, 600 pulses-a-day for 10 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham-rTMS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Real-rTMS
Number of subjects: 22
Study: 17436334

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 32

Group type: COMPARATOR
Intervention: Piggyback method
Number of subjects: 32
Study: 16011198

Group type: EXPERIMENTAL
Intervention: HIF-1alpha in proliferating phase
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: VEGF in proliferating phase
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: HIF-1alpha in involuting phase
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: VEGF in involuting phase
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Microvessel density (MVD) in proliferating phase
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Microvessel density (MVD) in involuting phase
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Correlation between HIF-1alpha and VEGF
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Correlation between HIF-1alpha and MVD
Number of subjects: 28
Study: 11931782

Group type: EXPERIMENTAL
Intervention: 165 microg/injection
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 330 microg/injection (less intense regimen)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 330 microg/injection (more intense regimen)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall treatment with intravitreous fomivirsen
Number of subjects: 150
Study: 9056060

Group type: EXPERIMENTAL
Intervention: Sucralfate (2000 mg twice daily for 5 days)
Number of subjects: 18
Study: 8140694

Group type: EXPERIMENTAL
Intervention: CDI (Color Doppler Imaging) assessment of retrobulbar circulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 0
Study: 3527513

Group type: EXPERIMENTAL
Intervention: Brotizolam (0.25 mg or 0.5 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Brotizolam to placebo switch
Number of subjects: 63
Study: 30382860

Group type: EXPERIMENTAL
Intervention: Hands-free body-weight-supported treadmill training (BWSTT) without assistance from handrails or assistive devices
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hands-free body-weight-supported treadmill training (BWSTT) with challenging mobility skills
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (HF and HF + C)
Number of subjects: 29
Study: 27735985

Group type: EXPERIMENTAL
Intervention: Whole-body vibration protocol at optimal frequency (WBV-OF) + Traditional rehabilitation programme (TRP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Traditional rehabilitation programme (TRP)
Number of subjects: 34
Study: 25577914

Group type: EXPERIMENTAL
Intervention: Baimai ointment, fomentation, functional exercises
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo, fomentation, functional exercises
Number of subjects: 43
Study: 23186965

Group type: EXPERIMENTAL
Intervention: Bromocriptine-QR (1.6 to 4.8 mg/day)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 515
Study: 21189853

Group type: COMPARATOR
Intervention: labetalol (0.25 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: esmolol (0.5 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: control (10 ml 0.9% saline)
Number of subjects: 75
Study: 18373383

Group type: EXPERIMENTAL
Intervention: Gepirone-ER (20 to 80 mg/day, most patients received 60 or 80 mg/day by week 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gepirone-ER
Number of subjects: 0
Study: 15747682

Group type: EXPERIMENTAL
Intervention: Single preoperative dose of prophylactic antibiotic with no postoperative antibiotics
Number of subjects: 215

Group type: COMPARATOR
Intervention: Preoperative dose of antibiotics with postoperative antibiotics for 7 days
Number of subjects: 215
Study: 12767655

Group type: EXPERIMENTAL
Intervention: Gamma VBT
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Beta VBT
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: True aorto-ostial lesions (Gamma VBT)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: True aorto-ostial lesions (Beta VBT)
Number of subjects: 133

Group type: COMPARATOR
Intervention: True aorto-ostial lesions (Placebo)
Number of subjects: 133
Study: 10498024

Group type: EXPERIMENTAL
Intervention: Heterologous barriers derived from hyaluronic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barrier gels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine usage of adhesion prevention measures
Number of subjects: 0
Study: 9019079

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 92
Study: 1734795

Group type: EXPERIMENTAL
Intervention: alpha-stat strategy
Number of subjects: 20

Group type: COMPARATOR
Intervention: pH-stat strategy
Number of subjects: 20
Study: 6203313

Group type: EXPERIMENTAL
Intervention: Anthralin 2% (Anthraderm)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Verucid (comparative drug)
Number of subjects: 72
Study: 31740271

Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30497620

Group type: EXPERIMENTAL
Intervention: Enhanced training in providing constructive feedback
Number of subjects: 836

Group type: COMPARATOR
Intervention: Untrained/signed group
Number of subjects: 836

Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Signature status (signed/unsigned)
Number of subjects: 836
Study: 27558180

Group type: EXPERIMENTAL
Intervention: Targeted decolonization with chlorhexidine and mupirocin
Number of subjects: 3173

Group type: EXPERIMENTAL
Intervention: Universal decolonization without screening
Number of subjects: 3173

Group type: EXPERIMENTAL
Intervention: Screening and isolation without decolonization
Number of subjects: 3173

Group type: COMPARATOR
Intervention: Baseline period
Number of subjects: 3173

Group type: EXPERIMENTAL
Intervention: Intervention periods
Number of subjects: 3173

Group type: EXPERIMENTAL
Intervention: Chlorhexidine susceptibility
Number of subjects: 3173

Group type: EXPERIMENTAL
Intervention: qacA or qacB gene presence
Number of subjects: 3173
Study: 24988179

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid treatment (1.9 g EPA and 1.5 g DHA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 23724240

Group type: EXPERIMENTAL
Intervention: Topical treatment plus immunotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical treatment with steroids and/or tacrolimus (Control)
Number of subjects: 60
Study: 19588187

Group type: EXPERIMENTAL
Intervention: Automatic bolus tracking (protocol 1)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Empiric scan delay (protocol 2)
Number of subjects: 79
Study: 17369783

Group type: EXPERIMENTAL
Intervention: Manual therapy for neck pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups of chronic neck pain subjects
Number of subjects: 0
Study: 15634731

Group type: EXPERIMENTAL
Intervention: Non-invasive transcranial direct current stimulation (tDCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 12112719

Group type: EXPERIMENTAL
Intervention: CT-based computer navigation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Free-hand method (after introduction of CAS)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Free-hand method (before introduction of CAS)
Number of subjects: 150
Study: 9697880

Group type: EXPERIMENTAL
Intervention: T cell disease
Number of subjects: 2090

Group type: EXPERIMENTAL
Intervention: Early pre-B (or null cell) disease
Number of subjects: 2090

Group type: EXPERIMENTAL
Intervention: Common or pre-B disease
Number of subjects: 2090

Group type: EXPERIMENTAL
Intervention: CD10-positive leukaemia
Number of subjects: 2090

Group type: EXPERIMENTAL
Intervention: CD10-negative leukaemia
Number of subjects: 2090
Study: 8538807

Group type: EXPERIMENTAL
Intervention: CareMap and nursing case management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CareMap development by multidisciplinary team
Number of subjects: 0
Study: 2172394

Group type: EXPERIMENTAL
Intervention: WC3 rotavirus vaccine
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Previous rotavirus infection, high levels of WC3 neutralizing antibody, maternal serotype 1 neutralizing antibody (titer >= 30)
Number of subjects: 206
Study: 1020905

Group type: EXPERIMENTAL
Intervention: Segmental epidural analgesia
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no epidural analgesia)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (epidural and control)
Number of subjects: 28
Study: 30856158

Group type: EXPERIMENTAL
Intervention: Qbrexza (glycopyrronium cloth)
Number of subjects: 0
Study: 25828260

Group type: EXPERIMENTAL
Intervention: Deliberative methods (4 different methods)
Number of subjects: 1774

Group type: COMPARATOR
Intervention: Reading materials only (RMO)
Number of subjects: 1774
Study: 22587973

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment combined with comprehensive rehabilitation therapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Comprehensive rehabilitation therapy only
Number of subjects: 124
Study: 21086596

Group type: EXPERIMENTAL
Intervention: Microwave resonance therapy with 'fluctuating' frequency and varied wave range
Number of subjects: 0
Study: 18489485

Group type: EXPERIMENTAL
Intervention: Injected non-setting calcium hydroxide (NS Ca(OH)(2)) dressing
Number of subjects: 150

Group type: COMPARATOR
Intervention: Spirally filled non-setting calcium hydroxide (NS Ca(OH)(2)) dressing
Number of subjects: 150
Study: 15890591

Group type: EXPERIMENTAL
Intervention: Intrarectal amifostine (1,500 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Subcutaneous amifostine (500 mg)
Number of subjects: 53
Study: 12917182

Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 10605192

Group type: EXPERIMENTAL
Intervention: Antiretroviral agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 8620521

Group type: EXPERIMENTAL
Intervention: Inhalation of 300,000 IU human natural IL-2 (hnIL-2) per day for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation of 150,000 IU human natural IL-2 (hnIL-2) per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation of 300,000 IU human natural IL-2 (hnIL-2) per day
Number of subjects: 0
Study: 1682600

Group type: EXPERIMENTAL
Intervention: Community-based maternity-care programme with trained midwives attending home deliveries and managing obstetric complications.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control area without midwives.
Number of subjects: 0
Study: 6755208

Group type: EXPERIMENTAL
Intervention: Continue treatment for 3 years
Number of subjects: 493

Group type: COMPARATOR
Intervention: Stop treatment after 18 months or 2 years
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Continue treatment for 2 years
Number of subjects: 493
Study: 31303526

Group type: EXPERIMENTAL
Intervention: High protein meal (41% of energy from protein, 29% from carbohydrates)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard meal (15% from protein, 46% from carbohydrate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High protein meal
Number of subjects: 0
Study: 29279062

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy tablets
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy drops
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both tablets and drops
Number of subjects: 41
Study: 27154364

Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil supplementation at a dose of 60mg/Kg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 24136296

Group type: EXPERIMENTAL
Intervention: Prednisone treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: TB‐IRIS patients
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-IRIS controls
Number of subjects: 44
Study: 22490180

Group type: EXPERIMENTAL
Intervention: Morning-preference participants tested in the morning
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Evening-preference participants tested in the afternoon
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Participants tested at their optimal times of day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Participants tested at their nonoptimal times of day
Number of subjects: 80
Study: 20836788

Group type: EXPERIMENTAL
Intervention: Geiger counter screening
Number of subjects: 30

Group type: COMPARATOR
Intervention: Portal radiation screening
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both devices
Number of subjects: 30
Study: 18540923

Group type: EXPERIMENTAL
Intervention: Gabapentin (1,500 mg or 5 pills at bedtime for 6 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 21
Study: 15743154

Group type: EXPERIMENTAL
Intervention: Vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study: 14750898

Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF) after high-dose chemotherapy with stem cell support
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF) in the treatment of established chemotherapy-induced febrile neutropenia
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard-dose chemotherapy
Number of subjects: 33
Study: 16617547

Group type: EXPERIMENTAL
Intervention: Integrated postpartum health-care program at CSLH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Public clinic services
Number of subjects: 0
Study: 8595995

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (high dosage)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 0
Study: 1883256

Group type: EXPERIMENTAL
Intervention: Clomipramine (up to 300 mg/d)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 520
Study: 6347211

Group type: EXPERIMENTAL
Intervention: Hepathrombin‐50,000‐Salbe
Number of subjects: 27

Group type: COMPARATOR
Intervention: Ointment base
Number of subjects: 27
Study: 30621746

Group type: EXPERIMENTAL
Intervention: Full-dose TNF inhibitors (adalimumab, etanercept, infliximab, golimumab)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Reduced-dose TNF inhibitors (approximately half the standard dose)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Full-dose TNF inhibitors
Number of subjects: 126

Group type: COMPARATOR
Intervention: Reduced-dose TNF inhibitors
Number of subjects: 126
Study: 30278544

Group type: EXPERIMENTAL
Intervention: Dezocine 0.15 mg/kg before anesthesia induction
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80